Satellos Bioscience Inc. (NASDAQ:MSLE) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Posted by Brian Himes on Sep 10th, 2026

Shares of Satellos Bioscience Inc. (NASDAQ:MSLE – Get Free Report) have earned a consensus rating of “Moderate Buy” from the seven analysts that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $19.75.

Several research firms recently issued reports on MSLE. Canaccord Genuity Group upgraded shares of Satellos Bioscience to a “moderate buy” rating in a report on Thursday, May 21st. Wall Street Zen upgraded Satellos Bioscience from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Satellos Bioscience in a research report on Friday, August 7th. HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Satellos Bioscience in a research note on Monday, August 17th. Finally, Wells Fargo & Company set a $18.00 target price on Satellos Bioscience in a research report on Thursday, July 9th.

View Our Latest Analysis on Satellos Bioscience

Satellos Bioscience Stock Performance

Satellos Bioscience stock opened at $10.02 on Thursday. The firm has a market cap of $212.62 million, a price-to-earnings ratio of -5.22 and a beta of 1.53. Satellos Bioscience has a 52-week low of $5.30 and a 52-week high of $13.39. The firm has a 50 day moving average price of $9.35 and a two-hundred day moving average price of $8.21.

Satellos Bioscience (NASDAQ:MSLE – Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.18). As a group, equities research analysts predict that Satellos Bioscience will post -2.08 EPS for the current fiscal year.

Hedge Funds Weigh In On Satellos Bioscience

A hedge fund recently raised its position in Satellos Bioscience stock. AWM Investment Company Inc. increased its stake in Satellos Bioscience Inc. (NASDAQ:MSLE – Free Report) by 41.9% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 305,000 shares of the company’s stock after acquiring an additional 90,000 shares during the quarter. AWM Investment Company Inc. owned 1.46% of Satellos Bioscience worth $2,338,000 at the end of the most recent reporting period.

About Satellos Bioscience

(Get Free Report)

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.